ODI Pharma AB announces sale of the skincare brand kandol. for 3.2 msek
ODI Pharma AB (“ODI” or the “Company”) announces today the sale of the skincare brand kandol. to Niclas Kappelin. The transaction, valued at 3.2 million SEK, includes the transfer of all inventories, production materials, trademarks, and copyrights associated with kandol. In connection with the transaction, CEO Derek Simmross and Chairman of the Board Volker Wiederrich will transfer 2,300,000 and 200,000 shares, off market, respectively to the buyer as part of the transaction.ODI announces that the Company has sold the skincare brand kandol. to the main shareholder Niclas Kappelin for 3.2